Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gallicchio, V. S.
Right arrow Articles by Hughes, N. K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gallicchio, V. S.
Right arrow Articles by Hughes, N. K.

International Journal of Cell Cloning, Vol 10, 99-104, Copyright © 1992 by AlphaMed Press

ORIGINAL ARTICLES

Influence of interleukin-3 on zidovudine (AZT)-induced in vitro toxicity to human hematopoietic progenitors

VS Gallicchio and NK Hughes
Department of Medicine, Microbiology and Immunology, Lucille P. Markey Cancer Center, University of Kentucky Medical Center, Lexington 40536- 0084.

Zidovudine (AZT), the antiviral drug used in the treatment of acquired immunodeficiency syndrome (AIDS), produces some toxicity to the hematopoietic system. Although several hematopoietic growth factors are currently undergoing clinical trials to evaluate their ability to modulate antiviral toxicity, there are scant data which support their ability to ameliorate AZT toxicity on hematopoietic progenitor cells when combined in vitro. We describe in this report the results of studies designed to evaluate in vitro the capacity of the cytokine interleukin-3 (IL-3), in dose-escalation fashion, to modulate AZT toxicity on normal human marrow derived granulocyte/erythroid/macrophage/megakaryocyte colony-forming units (CFU-GEMM), CFU-granulocyte/macrophage (CFU-GM) and erythroid burst- forming units (BFU-E). Colony formation for each progenitor was increased in the presence of IL-3 compared to cultures plated in its absence. In the presence of AZT (ID50 dose, used for each progenitor), IL-3 reduced AZT toxicity, with the most significant response observed for CFU-GEMM, indicating IL-3 may exert an effect on early, less differentiated hematopoietic progenitors. These studies indicate IL-3 may be an effective agent in reversing the hematopoietic toxicity associated with AZT; however, further in vivo studies are required before clinical use of IL-3 is advocated.


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. R. Difalco, L. Dufresne, and L. F. Congote
Efficacy of an Insulin-Like Growth Factor-Interleukin-3 Fusion Protein in Reversing the Hematopoietic Toxicity Associated with Azidothymidine in Mice
J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 449 - 454.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 1992 by AlphaMed Press.